Inhibrx Biosciences , Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company valued at $205.41 million, is navigating a critical phase in its development as it advances its oncology pipeline.

The blood–brain barrier is the biggest challenge to the development of drugs that target the CNS. Most capillary beds leak plasma contents between and across endothelial cells by way of window-like ...

Any lingering doubts over the feasibility of rolling out population-based cancer registries in low-income and middle-income countries ought to have been dispelled by the COVID-19 pandemic. Within ...